Long-term efficacy of acetylcholinesterase inhibitors on cognitive function. -Comparison between drugs.

Long-term efficacy of acetylcholinesterase inhibitors on cognitive function. -Comparison between drugs. - Long-term efficacy of acetylcholinesterase inhibitors on cognitive function.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014465

Enrollment

300

Registered

2014-07-14

Start date

2014-07-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Altzheimer&#39

Interventions

Galantamin is administered in a half of the patients agreed with this study. The starting dose of galantamin is 8 mg/day, and the maintenance dose is 16-24 mg/day. The study period is 12 months. Bl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Untreated Altzheimer's disease patients with MMSE score between 10 and 27 at screening.

Exclusion criteria

Exclusion criteria: The patients with allergy to cholinesterase inhibitors are excluded.

Design outcomes

Primary

Measure	Time frame
Mini Mental State Examination (MMSE) score change form baseline at 12 months treatment.	—

Secondary

Measure	Time frame
Mini Mental State Examination (MMSE) score change form baseline at 6 months treatment.	—

Countries

Japan

Contacts

Public ContactKana Tojo

Shinshu University of Medicine Neurology and Rheumatology

tkana@shinshu-u.ac.jp0263-37-2673

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026